Intravenous Calcium for Facilitating Recovery in Children Hospitalized with Pneumonia and low blood calcium without symptoms

Intravenous Calcium for Facilitating Recovery in Children Hospitalized with Pneumonia and Asymptomatic Hypocalcemia: A Randomized Controlled Study - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096172

Enrollment

100

Registered

2025-10-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J189- Pneumonia, unspecified organism

Interventions

Intervention1: Injection Calcium Gluconate: Injection calcium gluconate (10% w/v equivalent to elemental calcium of 8.9 mg/mL or 0.45 mEq/mL of calcium) and 5% dextrose will be mixed in 1:1 ratio to p

Eligibility

Inclusion criteria

Inclusion criteria: Children diagnosed with pneumonia/severe pneumonia based on WHO classification, requiring hospitalization and detected to be having asymptomatic hypocalcemia

Exclusion criteria

Exclusion criteria: 1.Children with known chronic comorbidities (e.g., congenital heart disease, immunodeficiency, neurological disorders). 2.Severe acute malnutrition 3.Children with complicated pneumonia (Empyema, lung abscess, massive pleural effusion) 4.Children presenting with shock, convulsions, requiring resuscitation or mechanical ventilation before enrolment. 5.Children who received oral/parenteral calcium within last 7 days before enrolment

Design outcomes

Primary

Measure	Time frame
Clinical resolution of pneumoniaTimepoint: Time for clinical resolution of pneumonia (in hours) from the time of enrolment	—

Secondary

Measure	Time frame
1.Resolution of chest retractions, or tachypnea 2.Oxygen requirement 3.Hospital stay 4.Serum calcium 5.Local & systemic adverse events (local site reactions, pain, swelling, redness at injection site, bradycardia, arrythmia, hypotension) Timepoint: 1.Time to resolution of chest retractions (in hours), or tachypnea (in hours) from time of enrolment 2.Duration of oxygen requirement (in hours) 3.Duration of hospital stay (in days) 4.Serum calcium at 24 & 48 hours after starting intravenous calcium gluconate 5.The frequency of local & systemic adverse events (local site reactions, pain, swelling, redness at injection site, bradycardia, arrythmia, hypotension) during 48 hours of intravenous calcium therapy	—

Measure

Time frame

1.Resolution of chest retractions, or tachypnea 2.Oxygen requirement 3.Hospital stay 4.Serum calcium 5.Local & systemic adverse events (local site reactions, pain, swelling, redness at injection site, bradycardia, arrythmia, hypotension) Timepoint: 1.Time to resolution of chest retractions (in hours), or tachypnea (in hours) from time of enrolment 2.Duration of oxygen requirement (in hours) 3.Duration of hospital stay (in days) 4.Serum calcium at 24 & 48 hours after starting intravenous calcium gluconate 5.The frequency of local & systemic adverse events (local site reactions, pain, swelling, redness at injection site, bradycardia, arrythmia, hypotension) during 48 hours of intravenous calcium therapy

—

Countries

India

Contacts

Public ContactDheeraj Shah

University college of medical sciences and GTB Hospital

shahdheeraj@hotmail.com8851872472

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026